ICAM

ICAM (Institute of Cancer and Antibody Medicine) is a Japanese biotechnology company focused on the discovery and development of novel therapeutic antibodies for the treatment of cancer. The company leverages its proprietary antibody engineering platform to generate high-affinity monoclonal antibodies targeting validated oncology markers such as ICAM-1 and EGFR. ICAM's research programs aim to address unmet medical needs in solid tumors by developing next-generation biologics with enhanced efficacy and safety profiles. By combining deep expertise in cancer biology with advanced protein engineering, ICAM is positioning itself as a key player in the Japanese oncology biopharma landscape.